Skip to search formSkip to main contentSkip to account menu

BMS 182248

Known as: BMS-182248 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
PURPOSE High levels (> 200,000 molecules per carcinoma cell) of the LewisY antigen are expressed on the surface of most (> 75… 
1997
1997
Purpose: The chimeric BR96–doxorubicin (DOX) immunoconjugate, BMS 182248, has induced remissions and cures of human lung… 
1994
1994
The toxicity of BMS-182248, an immunoglobulin (cBR96)-cytotoxic drug (doxorubicin) conjugate, was investigated in Sprague-Dawley…